RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory

The College of American Pathologists/American Society of Clinical Oncology recommends HER2 testing prior to initiation of targeted therapy for patients with advanced Gastroesophageal adenocarcinoma (GEA), using immunohistochemistry (IHC) followed by fluorescence in situ hybridization (FISH) in cases...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2022-04, Vol.35 (4), p.549-553
Hauptverfasser:	Jedrzkiewicz, Jolanta, Sirohi, Deepika, Uvejzovic, Nermin, Gulbahce, H. Evin
Format:	Artikel
Sprache:	eng
Schlagworte:	14/32 692/53/2423 692/699/67/1504/1477 Adenocarcinoma Adenocarcinoma - genetics Biomarkers, Tumor - genetics Breast Neoplasms Cancer Carcinoma Chromosome 17 Chromosomes, Human, Pair 17 - genetics Copy number ErbB-2 protein Esophagus Female Fluorescence in situ hybridization Humans Immunohistochemistry In Situ Hybridization, Fluorescence - methods Laboratories Laboratory Medicine Medicine Medicine & Public Health Pathology Receptor, ErbB-2 - genetics Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The College of American Pathologists/American Society of Clinical Oncology recommends HER2 testing prior to initiation of targeted therapy for patients with advanced Gastroesophageal adenocarcinoma (GEA), using immunohistochemistry (IHC) followed by fluorescence in situ hybridization (FISH) in cases with an equivocal (score 2 + ) result on IHC. The FISH results are considered indeterminate if the HER2 /CEP17 ratio is
ISSN:	0893-3952 1530-0285
DOI:	10.1038/s41379-021-00933-4